Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- 23 June 2015
- journal article
- research article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 16 (8), 908-918
- https://doi.org/10.1016/s1470-2045(15)00083-2
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Up-Regulation of PD-L1, IDO, and T regs in the Melanoma Tumor Microenvironment Is Driven by CD8 + T CellsScience Translational Medicine, 2013
- Targeting Oncogenic Drivers and the Immune System in MelanomaJournal of Clinical Oncology, 2013
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerThe New England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- The role of BRAF V600 mutation in melanomaJournal of Translational Medicine, 2012
- CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in HumansClinical Cancer Research, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response CriteriaClinical Cancer Research, 2009
- Partial residuals for the proportional hazards regression modelBiometrika, 1982
- The Efficiency of Cox's Likelihood Function for Censored DataJournal of the American Statistical Association, 1977